marked.bio

FAK/ALK/ROS1 inhibitor · small molecule

APG-2449

2 active trials across 2 of our biomarkers, targeting FAK/ALK/ROS1. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 2 2 Phase 1
ROS1 fusion 2 2 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of APG-2449.

  1. Ascentage Pharma Group 2

Trials

2 of 2 trials shown

  1. APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

    Recruiting Phase 1 Ascentage Pharma Group Started 2024Primary completion 2027-05 NCT06687070

    APG-2449pegylated liposomal doxorubicin

    Patients with histologically and/or cytologically confirmed ALK/ROS1 gene fusion positive non-small cell lung cancer and various advanced tumors.

    ALK fusionROS1 fusionPlatinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor

  2. APG-2449 in Patients With Advanced Solid Tumors

    Recruiting Phase 1 Ascentage Pharma Group Started 2019Primary completion 2027-12 NCT03917043

    APG-2449

    …stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and malignant pleural mesothelioma, e…

    ALK fusionROS1 fusionAdvanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer